AiViva Biopharma Receives FDA Clearance to Administer AIV001 in Facial Skin by Intradermal Injection for Nonmelanoma Skin Cancer
AIV001 is currently in development for evaluation in Superficial and Nodular Superficial Basal Cell Carcinoma (sBCC and nBCC) COSA MESA, Calif., Dec. 09, 2024 (Korea Bizwire) – AiViva Biopharma Inc., a clinical-stage biotechnology company, announced the receipt of FDA clearance for testing AIV001 (axitinib) by intradermal injection with their formulation in facial skin. AIV001 is [...]